Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literat

SUBMITTER: Huang X 

PROVIDER: S-EPMC6906351 | biostudies-literature | 2019 Oct-Dec

REPOSITORIES: biostudies-literature